Lexeo Therapeutics, Inc. Common Stock (LXEO) — Financial Flexibility Index
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a Financial Flexibility Index of -1.12x as of March 2026. Free cash flow of $-21.11 Million (operating CF $-21.14 Million minus capex $35.00K) represents -1% of total liabilities ($18.86 Million). Check LXEO strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lexeo Therapeutics, Inc. Common Stock Financial Flexibility Index (2020–2025)
Historical Financial Flexibility Index trend for Lexeo Therapeutics, Inc. Common Stock across 6 annual periods. See LXEO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Lexeo Therapeutics, Inc. Common Stock (2020–2025)
Year-by-year free cash flow to debt coverage for Lexeo Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see market value of Lexeo Therapeutics, Inc. Common Stock.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -4.46x | $-98.16 Million | $-98.56 Million | $22.02 Million | ▼ -66.3% |
| 2024 | -2.68x | $-80.67 Million | $-81.15 Million | $30.10 Million | ▼ -18.7% |
| 2023 | -2.26x | $-59.33 Million | $-59.50 Million | $26.27 Million | ▼ -783.9% |
| 2022 | -0.26x | $-53.66 Million | $-54.56 Million | $210.03 Million | ▼ -11.8% |
| 2021 | -0.23x | $-43.99 Million | $-44.18 Million | $192.46 Million | ▼ -154.9% |
| 2020 | -0.09x | $-3.13 Million | $-3.13 Million | $34.95 Million | — |